SlideShare a Scribd company logo
1 of 1
HIGHLY DIFFERENTIATED IN VITRO PRIMARY MUSCLE FIBER:
A NOVEL MODEL RECAPITULATING PATHOLOGIC FEATURES OF G93A SOD1 MOUSE
Background
Amyotrophic lateral sclerosis (ALS) is a highly debilitating
fatal disease in humans with life expectancy ranging from
two to five years after diagnosis. This pathology is
characterized by weakness, muscle atrophy and spasticity
leading to death in patients mostly due to respiratory failure
caused by impaired diaphragm contraction. Muscle atrophy
is believed to be triggered by the loss of upper motor
neurons (UMNs) in the cortex and of lower motor neurons
(LMNs) in brainstem and spinal cord1. Genetic defects in the
zinc/copper superoxide dismutase (SOD1) gene, has been
linked to familial and sporadic ALS. While this model has
been extensively used to study loss of MNs and
neuromuscular junctions, less attention has been given to
the potential role of impaired muscle development.
Objective
Investigate the possible pathophysiological link between
muscle development and neuromuscular junction loss in the
SOD1G93A mice by :
i. setting up an in-vitro model that could recapitulate the
defects in muscle observed in ALS.
ii. investigating the dynamics of fiber differentiation and
neuromuscular features in G93ASOD1 myofiber
cultures.
Discussion & Conclusions
These preliminary data secure this protocol as a robust model to
study highly differentiated fibers recapitulating muscle development
in SOD1G93A mice.
 Our findings from G93ASOD1 mice revealed that muscle
development and features of the post-synaptic apparatus are
impaired in fibers taken from young mice which are still
asymptomatic.
 Our data supports the hypothesis that muscle development could
be an independent trigger of neuromuscular junction loss and muscle
atrophy.
 This novel model could be used as a new tool to study time-based
development of neuromuscular structures in G93ASOD1 mice and to
test new therapeutic compounds for ALS.
VILMONT Valérie 1, CADOT Bruno 1, GOMES Rodrigues Edgar 1,2
1Myology Research Center, Sorbonne Universités, UPMC Université Paris, Paris, France, 2Instituto de Medicina Molecular, Lisbon, Portugal
Email address for correspondence: vilmont@myologygroup.net
Keywords: muscle, in-vitro differentiation, G93ASOD1
Model Set up
• Primary myoblasts were isolated from P7 transgenic pups
expressing the G93A mutant form of human SOD1 and from WT
littermates.
• Myoblasts proliferated to 70-80% confluence and were directed
to differentiate to advanced stages (Day 9-10) on Matrigel
support2.
• Features of high differentiation, such as:
triad formation (marked with DPHR) ,
movement of nuclei to the periphery ,
fiber thickness
were assessed at terminal differentiation (day 9).
• Three important post-synaptic features were also analyzed to
give an indication of the neuromuscular junction maintenance:
AchR (Acetylcholine receptor) clusters
MuSK/ phosphorylated MuSK
Rapsyn clusters
• Isolated fibers from symptomatic SOD1G93A mice as well as
from WT littermate were analyzed for the above post-synaptic
features to check for correlation between in-vitro differentiated
and in-vivo model.
In vitro DIFFERENTIATED FIBERS
Day 6 Day 9
Figure 1. A highly differentiated fiber showing peripheral nuclei and triads marked with DHPR
P7pups
Day 0
-Switch to
differentiation
medium + agrin
-Addition of
Matrigel
Myoblasts
Proliferation Differentiation
DHPR
References
1Wim Robberecht & Thomas Philips, Nat Rev Neuro, 2013
2Falcone S et al., EMBO Mol Med, 2014
3http://neuromuscular.wustl.edu/synmg.html
Acknowledgements
The authors are grateful to the following organizations for funding
Figure 2. AchR, MuSK and rapsyn localization at the
post-synaptic membrane upon agrin-induced AchR
clustering 3. Formation of this complex is important for the
maintenance of the post-synaptic structure and thereafter of
the neuromuscular junction.
Figure 7a. Comparison between SOD1 WT and SOD1G93A single fibers. In
SOD1G93A fibers, expression of Rapsyn, and MuSK is drastically reduced and the
pretzel structure of the AchR cluster is fragmented.
SYMPTOMATIC
Figure 3. Method for single fiber isolation. Symptomatic G93ASOD1 mouse showing
severe kyphosis and muscle atrophy. EDL muscles are sampled and flushed to obtain
single fibers. The latter are fixed and stained.
Results
I Post-synaptic features are affected throughout differentiation
G93ASOD1 MOUSE LIFESPAN
ASYMPTOMATIC
120daysP7 pups
SYMPTOMATIC
30days
Figure 4. Day 6 differentiated in-vitro fibers show
normal post-synaptic features expression and
localization. The fibers can be assimilated to
the asymptomatic phase of the G93ASOD1 mice
lifespan.
Day 9 in-vitro differentiated show expression of MuSK, phosphoMuSK and Rapsyn is lost to
different extent, while SOD1 WT littermate show normal expression of these post-synaptic
features. These alteration can be assimilated to the symptomatic phase of the
G93ASOD1mice lifespan.
G93ASOD1
Day6
G93ASOD1SOD1 WT
Day9
IV Isolated fibers obtained from symptomatic G93ASOD1 show post-synaptic alteration in correlating
with neuromuscular impairment seen in in-vitro differentiated fibers
a)
b)
Figure 7b. Comparison between SOD1 WT and G93ASOD1single fibers. In G93A
SOD1 fibers, expression of phosphorylayted MuSK is nearly absent.
III AchR clusters are impaired
Figure 6. Comparison between acetylcholine receptor clusters in WT and G93ASOD1 cultures.
a) The number of cluster per fiber is decreased in G93ASOD1 cultures. b) The length of AChR
clusters per fiber is decreased in G93ASOD1 cultures.
II Fiber differentiation is impaired
0
20
40
60
80
100
WT SOD1
%fiberswithperipheral
nuclei
0
10
20
30
40
50
WT SOD1
%fiberswithtriads
0
2
4
6
8
10
WT SOD1
Thickness(um)
Figure 5. Comparison between myofiber differentiation of WT and G93ASOD1 cultures. a) The %
of fibers with peripheral nuclei is decreased in G93ASOD1 cultures. b) The % of fibers with triads
is decreased in G93ASOD1 cultures. c) The thickness of fibers is decreased in G93ASOD1
cultures.
a) b) c)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
WT SOD1
Numberofclusterperfiber
a)a)
0
5
10
15
20
25
30
WT SOD1
Lengthofclusterperfiber
b)

More Related Content

What's hot

Plegable jonathan cardona vélez
Plegable jonathan cardona vélezPlegable jonathan cardona vélez
Plegable jonathan cardona vélezjcardonavelez
 
molecular markers in muscular dystrophy
molecular markers in muscular dystrophymolecular markers in muscular dystrophy
molecular markers in muscular dystrophyMalar Malar
 
Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...
Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...
Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...FranProfesor1
 
Wojciechowski stevens 2021_a_dynamic_duo
Wojciechowski stevens 2021_a_dynamic_duoWojciechowski stevens 2021_a_dynamic_duo
Wojciechowski stevens 2021_a_dynamic_duoFranProfesor1
 
Muthusamy_et_al-2015-Aging_Cell
Muthusamy_et_al-2015-Aging_CellMuthusamy_et_al-2015-Aging_Cell
Muthusamy_et_al-2015-Aging_CellLaura Sommerville
 
DTwohig-LiteratureReview-Prions_TheUPR_&MetalIons
DTwohig-LiteratureReview-Prions_TheUPR_&MetalIonsDTwohig-LiteratureReview-Prions_TheUPR_&MetalIons
DTwohig-LiteratureReview-Prions_TheUPR_&MetalIonsDaniel Twohig
 
Deglycosylation_of_ERdj3_and_Mutant_Variants
Deglycosylation_of_ERdj3_and_Mutant_VariantsDeglycosylation_of_ERdj3_and_Mutant_Variants
Deglycosylation_of_ERdj3_and_Mutant_VariantsCamden Holm
 
Wong J et al. - PLoS ONE - 2013
Wong J et al. - PLoS ONE - 2013Wong J et al. - PLoS ONE - 2013
Wong J et al. - PLoS ONE - 2013Jacob Wong
 
pschreiner_DissertationProposal
pschreiner_DissertationProposalpschreiner_DissertationProposal
pschreiner_DissertationProposalPatrick Schreiner
 
Kumar-igmposter_enhancer_2013_FINAL
Kumar-igmposter_enhancer_2013_FINALKumar-igmposter_enhancer_2013_FINAL
Kumar-igmposter_enhancer_2013_FINALshantanu kumar
 
Strauss_et_al_2015_with_supp (1)
Strauss_et_al_2015_with_supp (1)Strauss_et_al_2015_with_supp (1)
Strauss_et_al_2015_with_supp (1)Abigail Benkert
 
Nature comunication 2015 Poitelon
Nature comunication 2015 PoitelonNature comunication 2015 Poitelon
Nature comunication 2015 PoitelonMonica Ghidinelli
 
journal.pgen.1003895.PDF
journal.pgen.1003895.PDFjournal.pgen.1003895.PDF
journal.pgen.1003895.PDFYueqin Zhou
 

What's hot (18)

Plegable jonathan cardona vélez
Plegable jonathan cardona vélezPlegable jonathan cardona vélez
Plegable jonathan cardona vélez
 
molecular markers in muscular dystrophy
molecular markers in muscular dystrophymolecular markers in muscular dystrophy
molecular markers in muscular dystrophy
 
Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...
Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...
Alvarez kolberg edelbrock-sasselli_ortega_qiu_syrgiannis_mirau_chen_chin_weig...
 
Wojciechowski stevens 2021_a_dynamic_duo
Wojciechowski stevens 2021_a_dynamic_duoWojciechowski stevens 2021_a_dynamic_duo
Wojciechowski stevens 2021_a_dynamic_duo
 
Muthusamy_et_al-2015-Aging_Cell
Muthusamy_et_al-2015-Aging_CellMuthusamy_et_al-2015-Aging_Cell
Muthusamy_et_al-2015-Aging_Cell
 
Article_M2
Article_M2Article_M2
Article_M2
 
DTwohig-LiteratureReview-Prions_TheUPR_&MetalIons
DTwohig-LiteratureReview-Prions_TheUPR_&MetalIonsDTwohig-LiteratureReview-Prions_TheUPR_&MetalIons
DTwohig-LiteratureReview-Prions_TheUPR_&MetalIons
 
Chala kenenisa
Chala kenenisaChala kenenisa
Chala kenenisa
 
2015 GPR126
2015 GPR1262015 GPR126
2015 GPR126
 
Deglycosylation_of_ERdj3_and_Mutant_Variants
Deglycosylation_of_ERdj3_and_Mutant_VariantsDeglycosylation_of_ERdj3_and_Mutant_Variants
Deglycosylation_of_ERdj3_and_Mutant_Variants
 
Protein Science 2004
Protein Science 2004Protein Science 2004
Protein Science 2004
 
Wong J et al. - PLoS ONE - 2013
Wong J et al. - PLoS ONE - 2013Wong J et al. - PLoS ONE - 2013
Wong J et al. - PLoS ONE - 2013
 
pschreiner_DissertationProposal
pschreiner_DissertationProposalpschreiner_DissertationProposal
pschreiner_DissertationProposal
 
BIOL3200 PROPOSAL
BIOL3200 PROPOSALBIOL3200 PROPOSAL
BIOL3200 PROPOSAL
 
Kumar-igmposter_enhancer_2013_FINAL
Kumar-igmposter_enhancer_2013_FINALKumar-igmposter_enhancer_2013_FINAL
Kumar-igmposter_enhancer_2013_FINAL
 
Strauss_et_al_2015_with_supp (1)
Strauss_et_al_2015_with_supp (1)Strauss_et_al_2015_with_supp (1)
Strauss_et_al_2015_with_supp (1)
 
Nature comunication 2015 Poitelon
Nature comunication 2015 PoitelonNature comunication 2015 Poitelon
Nature comunication 2015 Poitelon
 
journal.pgen.1003895.PDF
journal.pgen.1003895.PDFjournal.pgen.1003895.PDF
journal.pgen.1003895.PDF
 

Similar to poster Brussels final

Muscle biopsy –INDICATIONS, processing and morphology.pptx
Muscle biopsy –INDICATIONS, processing and morphology.pptxMuscle biopsy –INDICATIONS, processing and morphology.pptx
Muscle biopsy –INDICATIONS, processing and morphology.pptxDrAbhisekkumar
 
Plegable Molecular biology.
Plegable Molecular biology.Plegable Molecular biology.
Plegable Molecular biology.jcardonavelez
 
International Journal of Molecular SciencesArticle
 International Journal of Molecular SciencesArticle International Journal of Molecular SciencesArticle
International Journal of Molecular SciencesArticleMargaritoWhitt221
 
Cereb. cortex 2009-knafo-586-92
Cereb. cortex 2009-knafo-586-92Cereb. cortex 2009-knafo-586-92
Cereb. cortex 2009-knafo-586-92shiraknafo
 
Considerations for Rigorous Pre-clinical Studies in Murine Muscular Dystrophy
Considerations for Rigorous Pre-clinical Studies in Murine Muscular DystrophyConsiderations for Rigorous Pre-clinical Studies in Murine Muscular Dystrophy
Considerations for Rigorous Pre-clinical Studies in Murine Muscular DystrophyInsideScientific
 
DMD and Dystrophin genetic based approach
DMD and Dystrophin genetic based approachDMD and Dystrophin genetic based approach
DMD and Dystrophin genetic based approachebinroshan07
 
Discussion on ALS and FTD
Discussion on ALS and FTDDiscussion on ALS and FTD
Discussion on ALS and FTDMasuma Sani
 
KDM5 epigenetic modifiers as a focus for drug discovery
KDM5 epigenetic modifiers as a focus for drug discoveryKDM5 epigenetic modifiers as a focus for drug discovery
KDM5 epigenetic modifiers as a focus for drug discoveryChristopher Wynder
 
Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...Ewelina Maliszewska-Cyna, PhD
 
Spines, plasticity, and cognition in alzheimer model mice.
Spines, plasticity, and cognition in alzheimer model mice.Spines, plasticity, and cognition in alzheimer model mice.
Spines, plasticity, and cognition in alzheimer model mice.shiraknafo
 

Similar to poster Brussels final (20)

Bordet-JPET-2007
Bordet-JPET-2007Bordet-JPET-2007
Bordet-JPET-2007
 
Scientifi c Journal of Multiple Sclerosis
Scientifi c Journal of Multiple SclerosisScientifi c Journal of Multiple Sclerosis
Scientifi c Journal of Multiple Sclerosis
 
Muscle biopsy –INDICATIONS, processing and morphology.pptx
Muscle biopsy –INDICATIONS, processing and morphology.pptxMuscle biopsy –INDICATIONS, processing and morphology.pptx
Muscle biopsy –INDICATIONS, processing and morphology.pptx
 
Myopathy
MyopathyMyopathy
Myopathy
 
Plegable Molecular biology.
Plegable Molecular biology.Plegable Molecular biology.
Plegable Molecular biology.
 
Thesis Sophie-Anne Lamour
Thesis Sophie-Anne LamourThesis Sophie-Anne Lamour
Thesis Sophie-Anne Lamour
 
International Journal of Molecular SciencesArticle
 International Journal of Molecular SciencesArticle International Journal of Molecular SciencesArticle
International Journal of Molecular SciencesArticle
 
Myopathy
MyopathyMyopathy
Myopathy
 
Smad
SmadSmad
Smad
 
Genes,brain & behavior1
Genes,brain & behavior1Genes,brain & behavior1
Genes,brain & behavior1
 
Cereb. cortex 2009-knafo-586-92
Cereb. cortex 2009-knafo-586-92Cereb. cortex 2009-knafo-586-92
Cereb. cortex 2009-knafo-586-92
 
DINESH K DHULL
DINESH K DHULLDINESH K DHULL
DINESH K DHULL
 
Gerasoudis poster 29-08-14
Gerasoudis poster 29-08-14Gerasoudis poster 29-08-14
Gerasoudis poster 29-08-14
 
Considerations for Rigorous Pre-clinical Studies in Murine Muscular Dystrophy
Considerations for Rigorous Pre-clinical Studies in Murine Muscular DystrophyConsiderations for Rigorous Pre-clinical Studies in Murine Muscular Dystrophy
Considerations for Rigorous Pre-clinical Studies in Murine Muscular Dystrophy
 
DMD and Dystrophin genetic based approach
DMD and Dystrophin genetic based approachDMD and Dystrophin genetic based approach
DMD and Dystrophin genetic based approach
 
Discussion on ALS and FTD
Discussion on ALS and FTDDiscussion on ALS and FTD
Discussion on ALS and FTD
 
KDM5 epigenetic modifiers as a focus for drug discovery
KDM5 epigenetic modifiers as a focus for drug discoveryKDM5 epigenetic modifiers as a focus for drug discovery
KDM5 epigenetic modifiers as a focus for drug discovery
 
Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...
 
Motor neuron disease
Motor neuron diseaseMotor neuron disease
Motor neuron disease
 
Spines, plasticity, and cognition in alzheimer model mice.
Spines, plasticity, and cognition in alzheimer model mice.Spines, plasticity, and cognition in alzheimer model mice.
Spines, plasticity, and cognition in alzheimer model mice.
 

poster Brussels final

  • 1. HIGHLY DIFFERENTIATED IN VITRO PRIMARY MUSCLE FIBER: A NOVEL MODEL RECAPITULATING PATHOLOGIC FEATURES OF G93A SOD1 MOUSE Background Amyotrophic lateral sclerosis (ALS) is a highly debilitating fatal disease in humans with life expectancy ranging from two to five years after diagnosis. This pathology is characterized by weakness, muscle atrophy and spasticity leading to death in patients mostly due to respiratory failure caused by impaired diaphragm contraction. Muscle atrophy is believed to be triggered by the loss of upper motor neurons (UMNs) in the cortex and of lower motor neurons (LMNs) in brainstem and spinal cord1. Genetic defects in the zinc/copper superoxide dismutase (SOD1) gene, has been linked to familial and sporadic ALS. While this model has been extensively used to study loss of MNs and neuromuscular junctions, less attention has been given to the potential role of impaired muscle development. Objective Investigate the possible pathophysiological link between muscle development and neuromuscular junction loss in the SOD1G93A mice by : i. setting up an in-vitro model that could recapitulate the defects in muscle observed in ALS. ii. investigating the dynamics of fiber differentiation and neuromuscular features in G93ASOD1 myofiber cultures. Discussion & Conclusions These preliminary data secure this protocol as a robust model to study highly differentiated fibers recapitulating muscle development in SOD1G93A mice.  Our findings from G93ASOD1 mice revealed that muscle development and features of the post-synaptic apparatus are impaired in fibers taken from young mice which are still asymptomatic.  Our data supports the hypothesis that muscle development could be an independent trigger of neuromuscular junction loss and muscle atrophy.  This novel model could be used as a new tool to study time-based development of neuromuscular structures in G93ASOD1 mice and to test new therapeutic compounds for ALS. VILMONT Valérie 1, CADOT Bruno 1, GOMES Rodrigues Edgar 1,2 1Myology Research Center, Sorbonne Universités, UPMC Université Paris, Paris, France, 2Instituto de Medicina Molecular, Lisbon, Portugal Email address for correspondence: vilmont@myologygroup.net Keywords: muscle, in-vitro differentiation, G93ASOD1 Model Set up • Primary myoblasts were isolated from P7 transgenic pups expressing the G93A mutant form of human SOD1 and from WT littermates. • Myoblasts proliferated to 70-80% confluence and were directed to differentiate to advanced stages (Day 9-10) on Matrigel support2. • Features of high differentiation, such as: triad formation (marked with DPHR) , movement of nuclei to the periphery , fiber thickness were assessed at terminal differentiation (day 9). • Three important post-synaptic features were also analyzed to give an indication of the neuromuscular junction maintenance: AchR (Acetylcholine receptor) clusters MuSK/ phosphorylated MuSK Rapsyn clusters • Isolated fibers from symptomatic SOD1G93A mice as well as from WT littermate were analyzed for the above post-synaptic features to check for correlation between in-vitro differentiated and in-vivo model. In vitro DIFFERENTIATED FIBERS Day 6 Day 9 Figure 1. A highly differentiated fiber showing peripheral nuclei and triads marked with DHPR P7pups Day 0 -Switch to differentiation medium + agrin -Addition of Matrigel Myoblasts Proliferation Differentiation DHPR References 1Wim Robberecht & Thomas Philips, Nat Rev Neuro, 2013 2Falcone S et al., EMBO Mol Med, 2014 3http://neuromuscular.wustl.edu/synmg.html Acknowledgements The authors are grateful to the following organizations for funding Figure 2. AchR, MuSK and rapsyn localization at the post-synaptic membrane upon agrin-induced AchR clustering 3. Formation of this complex is important for the maintenance of the post-synaptic structure and thereafter of the neuromuscular junction. Figure 7a. Comparison between SOD1 WT and SOD1G93A single fibers. In SOD1G93A fibers, expression of Rapsyn, and MuSK is drastically reduced and the pretzel structure of the AchR cluster is fragmented. SYMPTOMATIC Figure 3. Method for single fiber isolation. Symptomatic G93ASOD1 mouse showing severe kyphosis and muscle atrophy. EDL muscles are sampled and flushed to obtain single fibers. The latter are fixed and stained. Results I Post-synaptic features are affected throughout differentiation G93ASOD1 MOUSE LIFESPAN ASYMPTOMATIC 120daysP7 pups SYMPTOMATIC 30days Figure 4. Day 6 differentiated in-vitro fibers show normal post-synaptic features expression and localization. The fibers can be assimilated to the asymptomatic phase of the G93ASOD1 mice lifespan. Day 9 in-vitro differentiated show expression of MuSK, phosphoMuSK and Rapsyn is lost to different extent, while SOD1 WT littermate show normal expression of these post-synaptic features. These alteration can be assimilated to the symptomatic phase of the G93ASOD1mice lifespan. G93ASOD1 Day6 G93ASOD1SOD1 WT Day9 IV Isolated fibers obtained from symptomatic G93ASOD1 show post-synaptic alteration in correlating with neuromuscular impairment seen in in-vitro differentiated fibers a) b) Figure 7b. Comparison between SOD1 WT and G93ASOD1single fibers. In G93A SOD1 fibers, expression of phosphorylayted MuSK is nearly absent. III AchR clusters are impaired Figure 6. Comparison between acetylcholine receptor clusters in WT and G93ASOD1 cultures. a) The number of cluster per fiber is decreased in G93ASOD1 cultures. b) The length of AChR clusters per fiber is decreased in G93ASOD1 cultures. II Fiber differentiation is impaired 0 20 40 60 80 100 WT SOD1 %fiberswithperipheral nuclei 0 10 20 30 40 50 WT SOD1 %fiberswithtriads 0 2 4 6 8 10 WT SOD1 Thickness(um) Figure 5. Comparison between myofiber differentiation of WT and G93ASOD1 cultures. a) The % of fibers with peripheral nuclei is decreased in G93ASOD1 cultures. b) The % of fibers with triads is decreased in G93ASOD1 cultures. c) The thickness of fibers is decreased in G93ASOD1 cultures. a) b) c) 0 0.2 0.4 0.6 0.8 1 1.2 1.4 WT SOD1 Numberofclusterperfiber a)a) 0 5 10 15 20 25 30 WT SOD1 Lengthofclusterperfiber b)